peter powchik  regeneron pharmaceuticals  inc  zoominfocom peter z powchik  croton on hudson ny  intelius sign in we found peter z powchik in croton on hudson ny peter z powchik intelius found that peter z powchik is a male between  and  years old from croton on hudson ny we have connected them to  addresses  phones and  relatives or associates get report now age peter z powchik is in his s peter has lived in croton on hudson ny wurtsboro ny great neck ny peters relatives olivia sklar trevor powchik ava powchik sk olivia peter z powchik zodiac signcancer gendermale professional status head clinical development  regulatory affairs at regeneron pharmaceuticals  inc get report now want to know more about peter get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about peter or use our people search engine to find others get background check on peter z powchik get a criminal check on peter z powchik get a public record report on peter z powchik get a people search report on peter z powchik peter z powchiks contact information known cities lived in find out where peter z powchik has lived as well as peter z powchiks phone numbers and email addresses peter z powchik has lived in  states new york address for peter z powchik  g l croton on hudson ny has lived in croton on hudson ny wurtsboro ny get full address report phone numbers associated with peter z powchik    croton on hudson ny    berkeley heights nj    croton on hudson ny get full phone report email addresses associated with peter z powchik pkcom get email report peter z powchiks professional information information regarding peter z powchiks professional history find out previous places peter z powchik has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act peter z powchik has worked at  places company regeneron pharmaceuticals  inc title head clinical development  regulatory affairs company chugai biopharmaceuticals  inc title vice presidentoperations peter z powchiks experience title head clinical development  regulatory affairs company regeneron pharmaceuticals  inc job details public company  employees regn biotechnology industry title vice presidentoperations company chugai biopharmaceuticals  inc job details company size  mil to less than  mil  employee range less than  additional professional information on peter z powchik see peter z powchiks linkedin profile peter z powchiks social network and potential email matches find out potential social network profiles and potential email usernamed for peter z powchik peter z powchiks known social networks and potential email matches find all of peter z powchiks social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches peter powchik username matches peterpowchik powchikpeter peterpowchik powchikpeter peterpowchik powchikpeter peterpowchik powchikpeter ppowchik popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches p powchik intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here peter powchik regeneron pharmaceuticals inc profile  biography  bloomberg feedback peter powchik senior vpclinical development regeneron pharmaceuticals inc career history senior vpclinical development regeneron pharmaceuticals present senior vpchief medical ofcr chugai pharma usa llc  website wwwregeneroncom corporate information address  old saw mill river road tarrytown ny  united states phone  fax  web url wwwregeneroncom from the web personal information education new york university school of medicine md sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data regn peter powchik insider trades for regeneron pharmaceuticals inc bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close regeneron pharmaceuticals inc nasdaq regn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus regeneron pharmaceuticals inc after hours  quotes are delayed by  min jul    pm regn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual peter powchik dr peter powchik md is senior vice presidentclinical development at regeneron pharmaceuticals inc dr powchik was previously employed as chief medical officer  senior vice president by chugai pharma usa llc vpclinical development  medical affairs by novartis pharmaceuticals corp a principal by pfizer inc and senior medical director by sunovion pharmaceuticals inc he received his doctorate degree from new york university transactions date shares transaction value     gift at  per share      gift at  per share      gift at  per share      gift at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr p roy vagelos chairman dr leonard s schleifer president chief executive officer  director mr robert e landry chief financial officer  senior vpfinance dr george damis yancopoulos director  chief scientific officer dr peter powchik senior vice presidentclinical development dr neil stahl executive vpresearch  development ms beth f levine senior vice president  chief compliance officer dr jay s markowitz senior vice presidentportfolio management mr robert j terifay senior vice presidentcommercial dr janet van adelsberg senior directorimmunology  inflammation dr alan shuldiner vice presidenttranslational genetics mr daniel p van plew svp gmindustrial operations  product supply dr n anthony coles director dr huda y zoghbi director dr bonnie l bassler director mr christopher fenimore chief accounting officer vp  controller mr potoula gjidija headmedia contacts ms hala mirza headcorporate communications dr manisha a narasimhan investor relations contact dr michael s aberman senior vpstrategy  investor relations ms sally a paull senior vice presidenthuman resources mr joseph j larosa secretary senior vice president  general counsel dr ned braunstein senior vice presidentregulatory affairs dr marc tessierlavigne independent director ms christine a poon independent director mr arthur frederick ryan independent director mr george l sing independent director dr joseph l goldstein independent director mr charles a baker independent director dr michael s brown independent class i director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest arenault profit leaps but shares decline abelgiums inflation rate picks up pace agerman consumer prices rise faster than expected arussia retaliates to new sanctions by telling us to cut diplomats afrench economy expands  in the second quarter abig six leave border adjustment out of tax principles akids are training to be ceos and spies at these specialized summer camps aamericans are so uncomfortable asking for money that we’ve resorted to this instead aoil pauses ahead of us rig data but  weekly gain in sight a weird things i found out about corporate america in my first  hours aubs credit suisse profits up after strategy shift astudent loan companies to feds tell states to stop regulating us abritishmade seedlip aims to woo the nondrinking crowd aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  peter powchik regeneron pharmaceuticals inc svp clinical development  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   peter powchik svp clinical development regeneron pharmaceuticals inc email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for peter powchik at regeneron pharmaceuticals inc peter powchik works as svp clinical development  regeneron pharmaceuticals inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more leads or mediamarketing prospecting automation start a free trial now recent related news  brooklyn spectacles debuts flagship store  harlem family dental bankruptcy  vburger to open  regeneron pharmaceuticals inc regn peter powchik vice president of clinical development exercised options on  shares of common stock at prices ranging from  to  per share on aug  in a transaction worth  on the next day he sold  shares of common stock at prices ranging from  to  per share in a transaction worth   people in this article peter powchik  sec receives insider trading form involving regeneron pharmaceuticals  regn tarrytown new york was involved in the following insider trading activity on a form  filed with the us securities and exchange commission insider peter powchik title senior vice president clinical development  reg date released august   date of action august   action acquired shares  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share and  shares of common stock at  action disposed shares  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at  per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share  shares of common stock at   per share and  shares of common stock at   per share now holds  explanation of responses  represents volumeweighted average price of sales of  shares of company stock on august   at prices ranging from  to   people in this article peter powchik learn more about peter powchik and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about peter powchik and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved exercise or conversion by peter powchik of  shares of regeneron pharmaceuticals subject to rule  regn  macroaxis research hub sign in sign in new account about macroaxis settings plans  pricing toggle menu toggle fullscreen  markets equities portfolios stories × my equities investing ideas free tools world markets map cryptocurrency center equity research company directory insider directory buy or sell recommendation pair correlation stocks correlation pattern recognition watchlist analysis services technology overview solution methodology acknowledgement product tour faqs about us about macroaxis contact us terms of use privacy policy advertising        follow quintiles imsvertex pharmaceuticalsendo internationalabbott laboratoriesleonard schleiferroy vagelosp vagelos world us regeneron pharmaceuticals story equity search company directory suggest portfolio backtest watchlist analyze correlations view transactions check volatility import equities summary performance fundamentals technicals recommendation profile essentials valuation headlines leaders hype analysis diagnosticsdashboard upgrade to remove ads regeneron pharmaceuticals inc  usd      macroaxis does not monitor all media channels or aggregates social signals for regeneron pharmaceuticals but even though we do not provide professionalgrade financial sentiment analysis on regeneron pharmaceuticals we do publish noisefree headlines that can be used to derive useful patterns or even a trading strategy for regeneron pharmaceuticals additionally take a look at regeneron pharmaceuticals hype analysis regeneron pharmaceuticals correlation and regeneron pharmaceuticals performance exercise or conversion by peter powchik of  shares of regeneron pharmaceuticals subject to rule bat wwwprnewswirecomapril  filed transaction by regeneron pharmaceuticals officer exercise or conversion of derivative security exempted pursuant to rule bread more   published over three months agoview all stories for regeneron pharmaceuticals  regeneron pharmaceuticals hype analysisregeneron pharmaceuticals inc insider trading alert for exercise of nonqualified stock option right to buy by peter powchik svp clinical development on april   this event was filed by regeneron pharmaceuticals with sec on  statement of changes in beneficial ownership  sec form  peter powchik is currently serves as senior vice president  clinical development of regeneron pharmaceut did you try thisrun price transformation now   price transformationuse price transformation models to analyze depth of different equity instruments across global marketshide  view all  next  launch price transformationcurrent assetcurrent asset comparative analysis  current asset       regeneron pharmaceuticals comparables regeneron pharmaceuticals is currently under evaluation in current asset category among related companies current asset is all of companys assets that can be used to pay off current liabilities within current fiscal period or over next  months current asset includes cash or cash equivalents accounts receivable shortterm investments and the portion of prepaid liabilities which will be paid within next  months because these assets are easily turned into cash they are sometimes referred to as liquid assetsmorepeersyour trending equities t         att profile att dashboard att technical analysis backtest att att news timeline att fundamentals trends bby         best buy profile best buy dashboard best buy technical analysis backtest best buy best buy news timeline best buy analyst consensus best buy fundamentals trends tgt         target profile target dashboard target technical analysis backtest target target news timeline target analyst consensus target fundamentals trends cvx         chevron profile chevron dashboard chevron technical analysis backtest chevron chevron news timeline chevron analyst consensus chevron fundamentals trends cvs         cvs health profile cvs health dashboard cvs health technical analysis backtest cvs health cvs health analyst consensus cvs health fundamentals trends hd         home depot profile home depot dashboard home depot technical analysis backtest home depot home depot news timeline home depot analyst consensus home depot fundamentals trends intc         intel profile intel dashboard intel technical analysis backtest intel intel news timeline intel analyst consensus intel fundamentals trends met         metlife profile metlife dashboard metlife technical analysis backtest metlife metlife news timeline metlife analyst consensus metlife fundamentals trends ibm         international business profile international business dashboard international business technical analysis backtest international business international business news timeline international business analyst consensus international business fundamentals trends wfc         wells fargo profile wells fargo dashboard wells fargo technical analysis backtest wells fargo wells fargo news timeline wells fargo analyst consensus wells fargo fundamentals trends c         citigroup profile citigroup dashboard citigroup technical analysis backtest citigroup citigroup news timeline citigroup analyst consensus citigroup fundamentals trends aa         alcoa profile alcoa dashboard alcoa technical analysis backtest alcoa alcoa news timeline alcoa analyst consensus alcoa fundamentals trends aapl         apple profile apple dashboard apple technical analysis backtest apple apple news timeline apple analyst consensus apple fundamentals trends aal         american airlines profile american airlines dashboard american airlines technical analysis backtest american airlines american airlines news timeline american airlines analyst consensus american airlines fundamentals trends ups         united parcel profile united parcel dashboard united parcel technical analysis backtest united parcel united parcel news timeline united parcel analyst consensus united parcel fundamentals trends s         sprint profile sprint dashboard sprint technical analysis backtest sprint sprint news timeline sprint analyst consensus sprint fundamentals trends updating transaction report was successfully generated   macroaxis llc all rights reserved   insiders companies contact us feedback widgets business and industry business business wire  free online library printer friendly  articles and books periodicals literature keyword title author topic the free library  business and industry  business  business wire the free library  business and industry  business international  business wire browse business wire by date business wire a wholly owned subsidiary of berkshire hathaway is the global market leader in commercial news distribution thousands of member companies and organizations depend on business wire to transmit their fulltext news releases regulatory filings photos and other multimedia content to journalists financial professionals investor services regulatory authorities and the general public worldwide  jan feb mar  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  jan feb mar apr may jun jul aug sep oct nov dec  nov dec publications by namepublications by dateauthorsliterature ad eo pt uz before      a b c d e f g h i j k l m n o p q r s t u v w x y z a b c d e f g h i j k l m n o p q r s t u v w x y z terms of use  copyright   farlex inc  feedback  for webmasters   peter powchik of regeneron pharmaceuticals inc executive profile   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center regeneron pharmaceuticals inc  regn morningstar rating add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  peter powchik peter powchik senior vice president clinical development profile connections biography dr peter powchikmd   has been senior vice president clinical development since joining the company in october  prior to joining the company dr powchik was employed at several pharmaceutical companies serving as senior vice president and chief medical officer of chugai pharma usa a position he held from may  until october  from april  until may  he held various senior clinical development positions at novartis pharmaceuticals corporation most recently as vice president us clinical development and medical affairs dr powchik held various clinical development positions with sepracor inc and pfizer inc from october  to april  dr powchik received his md from new york university school of medicine board membership peter powchik is not a member of any boards   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft regeneron names peter powchik md senior vice president of clinical development  free online library printer friendly  articles and books periodicals literature keyword title author topic the free library  business and industry  business  business wire  october   the free library  business and industry  business international  business wire  october   the free library  date      october      business wire regeneron names peter powchik md senior vice president of clinical development linkpage citation pagelink page url html link a hrefhttpswwwthefreelibrarycomregeneronnamespeterpowchikcmdcseniorvicepresidentofaa citations mla style regeneron names peter powchik md senior vice president of clinical development the free library  business wire  jul  httpswwwthefreelibrarycomregeneronnamespeterpowchikcmdcseniorvicepresidentofa chicago style the free library sv regeneron names peter powchik md senior vice president of clinical development retrieved jul   from httpswwwthefreelibrarycomregeneronnamespeterpowchikcmdcseniorvicepresidentofa apa style regeneron names peter powchik md senior vice president of clinical development nd the free library  retrieved jul   from httpswwwthefreelibrarycomregeneronnamespeterpowchikcmdcseniorvicepresidentofa tarrytown ny  regeneron pharmaceuticals inc nasdaq regn announced today the appointment of peter powchik md as senior vice president of clinical development to lead the companys clinical development efforts dr powchik will report to george yancopoulos md phd president regeneron research laboratories regenerons product candidates are being tested in an expanding number of latestage clinical trials in cancer eye disease and inflammatory conditions remarked dr yancopoulos dr powchik has played a key role at major pharmaceutical companies in guiding important products successfully through the clinical and regulatory process his demonstrated expertise and broad experience will be particularly valuable as our clinical development efforts advance peter will lead our growing clinical team which includes the recent addition of an oncologist and an ophthalmologist to senior clinical positions regeneron has exciting drug candidates progressing through clinical development that address significant unmet medical needs and the stated goal of advancing two new antibody candidates into the clinic each year beginning in  added dr powchik i look forward to joining regenerons management team and overseeing this ambitious drug development effort dr powchik joins regeneron from chugai pharma usa where he was senior vice president and chief medical officer there he was responsible for development activities for oncology cardiology and gastrointestinal product candidates he held senior clinical development positions with novartis pharmaceuticals corporation sepracor inc and pfizer inc before joining chugai dr powchik brings expertise in clinical development and in positioning new products for commercialization in the pharmaceutical industry he played a significant role in the development and commercialization of important new products prior to his work in the pharmaceutical industry dr powchik was on the faculty of the mount sinai school of medicine in new york city he received an md degree from the new york university school of medicine about regeneron pharmaceuticals regeneron is a biopharmaceutical company that discovers develops and intends to commercialize therapeutic medicines for the treatment of serious medical conditions regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer eye diseases and inflammatory diseases and has preclinical programs in other diseases and disorders this news release discusses historical information and includes forwardlooking statements about regeneron and its products programs finances and business all of which involve a number of risks and uncertainties such as risks associated with preclinical and clinical development of our drug candidates determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our drug candidates competing drugs that are superior to our product candidates unanticipated expenses the availability and cost of capital the costs of developing producing and selling products the potential for any collaboration agreement including our agreement with the sanofiaventis group to be canceled or to terminate without any product success risks associated with third party intellectual property and other material risks a more complete description of these and other material risks can be found in regenerons filings with the united states securities and exchange commission sec including its form k for the year ended december   and form q for the quarter ended june   regeneron does not undertake any obligation to update publicly any forwardlooking statement whether as a result of new information future events or otherwise unless required by law copyright  business wire no portion of this article can be reproduced without the express written permission from the copyright holder copyright  gale group all rights reserved gale group is a thomson corporation company article details printer friendly citelink email feedback publicationbusiness wire dateoct   wordsprevious articlevibo deploys comverse insighttm open services environment and advanced messaging services for its g networknext articlezacks analyst blog highlights alexza pharmaceuticals and corcept therapeutics topics executives pharmaceutical industry officials and employees vice presidents organizations related articles james w fordyce leaves regeneron board regeneron names new vice president quality assurance  regulatory affairs regeneron promotes yancopoulos to chief scientific officer also names valenzuela vice president regeneron announces executive appointments yancopoulos named president regeneron research laboratories chief scientific officer and executive regeneron appoints marketing and sales executive and names two other executives to strengthen preclinical and clinical development groups regeneron names ross grossman vice president of human resources regeneron and novartis form strategic collaboration to develop and commercialize the il trap in rheumatoid arthritis and other indications dr george yancopoulos elected to national academy of sciences regeneron chief scientific officer among  scientists honored regeneron to webcast presentations at two investor conferences regeneron announces participation in panel discussions at rbc capital markets conference publications by namepublications by dateauthorsliterature ad eo pt uz before      a b c d e f g h i j k l m n o p q r s t u v w x y z a b c d e f g h i j k l m n o p q r s t u v w x y z terms of use  copyright   farlex inc  feedback  for webmasters   business wire october    free online library printer friendly  articles and books periodicals literature keyword title author topic the free library  business and industry  business  business wire  october   the free library  business and industry  business international  business wire  october   the free library  date      october      business wire articles from business wire october    out of  articles next title author type words im there for you baby radio show presents october lineup  entrepreneurship alive and thriving in nonprofit real estate and internet sectors  we all live in a watershed premiers on kcet october nd  access to education deemed a top priority to the  most influential us hispanics   inaugural denver marathon debuts in the mile high city   midatlantic venture capital directory now available directory  st century holding company anticipates record earnings for   k sports announces nba k soundtrack dan the automator presents k now available sound recording review  k sports announces nhlr k for playstationr now available  i infotech to automate san jose police departments citation process  m completes acquisition of nylonge corp   million private branded handsets will be shipped in  according to abi research  a virtual tree grows in baltimore  a large part of financial innovation in recent years has been related to securitization credit derivatives or a combination of the two  introduction to structured finance  a new chicago holding company is building success from the ground up  a report of the risk forecasts for each country within western europe  am best releases lifehealth edition of bests aggregates  averagesonlineunited states  canada  aba retirement funds introduces two plan features retirement date funds and roth k  ableauctions reports on annual general meeting  abraxas to present at ipaa oil  gas investment symposium in san francisco  accelrys reports world class customer satisfaction for its scientific operating platform  accessing capital through pipes focus of los angeles venture association october   panel  acco brands to webcast third quarter earnings call november    acme united corporation board approves cash dividend  activepoint helps bf products net more sales and fence out the competition with easyflip ecatalog  activision appoints brian hodous chief customer officer  acuity brands promotes mary bruce edmonds to vice president risk management  adding multimedia hp energizes enterprise imaging and printing growth with revitalized sales approach expanded portfolio  adding multimedia pall to expand life sciences manufacturing in puerto rico  adomo selects mimosa nearpoint to improve the protection and availability of microsoft exchange information  advanced marketing services inc announces annual meeting of stockholders  advanced neuromodulation systems receives australian regulatory and reimbursement approval for rechargeable chronic pain system  advanced technetix commits to atmel and arm for security for its patented accesskey  advectis builds blitzdocsr connector for citigroup  aecom maunsell merge with cansult  aero force one fan club ticket packages on sale now for aerosmith route of all evil tour stops in tampa and west palm beach  aert announces third quarter gross sales  aethlon medical to present at italian embassy avian and human influenza pandemic conference  aetna introduces powerful interactive personal health record  ageia physx sdk v brings dynamic interactive realism to microsoft windows vista bit  linux environments  aim investmentsr launches new retirement planning tool with aim planforward module   airgas appoints robert m mclaughlin as chief financial officer  airgas names van roden to board of directors  aisling capital joins i wistar morris iii and intersouth partners as a lead investor in cempra pharmaceuticals  akamai to hold third quarter investor conference call on thursday october th at  pm et  akeena solar expands operations in fresno california  alanco closes  million longterm debt financing  alanco provides update on auditor opinion  alcoa launches  worldwide month of service to make global impact thousands of employees to volunteer in communities around the world  alkermes expands addiction franchise to include development program for oral products clinical report  allegro wins energy software contract for noble energy inc  alliance boots wholesale supply chain gets performance boost with manhattan associates integrated planning solutionstm  alltel completes purchase of midwest wireless  along mobile technologies inc and union mobile pay ltd announce a strategic alliance to create chinas largest mobile phone payment system  alpha industries inc relocates national headquarters  altana pharma announces strategic realignment of the us business company overview  ambassadors group announces q  earnings conference call  america first apartment investors inc completes acquisition of north carolina apartment portfolio for  million  americas strivectinsdr voted best antiwrinkle cream in france  american campus communities opens  million thirdparty development at the university of california irvine  american dairy inc completes private placement  american sporting goods selects tradecard to increase supply chain agility and drive growth  american superconductor wins new hts wire order from korean technology developer  americas sap users group to host customer relationship management forum  americredit announces new warehouse financing agreement  ameriprise financial completes first year as an independent public company  ami semiconductor to exhibit at fsa expo  amkor amends consent solicitation  ample communications signs broadband technology as distributor in the uk  amulet technologiesr awarded us patent on its invention of graphical user interface engine for embedded systems  an entrepreneurial edge using technology to boost efficiency and productivity featured on kauffman eventuringtm site  analysis of past trends in the french securities brokerage industry is key to predicting its future  analyze the nda  nme firstcycle success rates and trends  apache and nec electronics collaborate to address the systeminpackage sip power integrity challenge  appriver removes limits on mailbox storage for hosted microsoft exchange service letter to the editor  archstone consulting forecasts lowest retail sales increase since  for upcoming holiday season  ardencetm releases v of its softwarestreaming platform  ardent acquisition corp to acquire avantair inc  ariba extends spend management days  arizona land and the shidler group to create west coast office reit  ascent solar aims for  centskwhr electricity production from its thinfilm modules  aspca launches aspca pet health insurance  astoria announces jack daly worldclass sales coach  speaker returns to dallas to help business professionals and the rise school  atlas mining company applies for large mine permit at dragon mine  auction of austin condos draws crowd in jp king auction resulting in complete sellout  aurora imaging technology names william valters vice president of sales  autonomic software announces universal micro agent  avago technologies master scientist to receive prestigious ieee fellow award at  international ultrasonics symposium  avst to deliver webinar on the methods and benefits of unifying communications for the education market  axcelis announces key design win at major asian memory chipmaker for new optima hd imax molecular implant system  axentis ceo to speak at wachovia securities technology and services conference  axesstel announces new series of g gateways converging evdo rev a data wifi router and ethernet switch  b braun awarded major home infusion pump contract by coram specialty infusion services company overview  bank of marin announces stock repurchase program  bank of the ozarks inc announces third quarter  earnings release date and conference call  bank of the west relies on flexible fiserv technology and outsourced services to evolve and grow mortgage lending business company overview  bankatlantic announces retail expansion into orlando market  bazaarvoice analysis reveals that positive online reviews outweigh negative reviews  to   bbn technologies names joe alwan vice president and general manager of its growing avoke call center analytics business  beam global spirits  wine inc selects the licensing company for portfolio brand extensions company overview  bear stearns hires antoine dijkstra and dominique favillier to bolster its strategic finance expansion in europe  beasley broadcast group to acquire wjbrfm in wilmington delaware for  million  beijing medpharm corporation names national sales manager for china  bioreference laboratories announces extension of provider participation agreement with united healthcare to include oxford health plans effective january   bioenergy texas welcomes nasdaq  bioscience industry leaders will gather in one place on oct  biotech   bisysr alternative investment services earns top ranking in administration category from alpha awards  bit group usability team improves dentalcareernetworkcoms renewal rate by  percent  black dragon resources produces approximately  barrels or equivalent for september  blue moonr wins top awards at the th annual great american beer festivalr  bluegreen corporation completes  million vacation ownership receivables term securitization with bbt  bni asks isnt networking just a fad  boc gases to break ground for beloit air separation plant company overview  boyden ceo addresses henley management college on succession planning company overview  bracewell  giuliani ranks no  in the nation among best law firms for women  brown jordan international inc extends exchange offer  bruce gamble joins alvarez  marsal real estate advisory services as managing director and head of southeast practice  bryan kelly joins stronghold management team  buckeye ventures inc reports energy king acquisition  buena vista records and the baby einstein company present a new musical companion for little ones  baby einsteintm playdate fun available october    bugs manufacturing subsidiary names new president  burger king corporation selects megapaths managed ip services to securely connect franchise sites across north america  business process outsourcing provider motif inc recruits former president of acs hr solutions inc as its new us based ceo  business wire to host media breakfast conference on the past present and future of public relations  cadiz announces appointment of new board member  cadwalader expands regulatory practice with addition of steven lofchie  calient networks partners with cornet technology inc to expand federal networks market success  california iso standardizes on actuate for realtime energy consumption reporting  california pacific medical center donates another  million to help uninsured  california pizza kitchen opens at foxwoods resort casino  canopy financial and subimo partner to launch decision support tools for financial institutions  cantel medical corp to hold conference call to discuss fourth quarter and fiscal  results  cardiovascular biotherapeutics appoints grant gordon to vice chairman of board  carfax expands accident information  cartoon network completes production on first original liveaction movie reanimated  castelle to exhibit its network fax servers at the aiim ecm solutions seminar in minneapolis  catalina marketing announces the earnings release date for its quarter ending september    caxtoniseman capital and royal palm capital partners acquire american residential services from servicemaster  ccatsm san diego provides awards to new robotics technologies  cdc games signs exclusive agreement to host the lord of the rings onlinetm game in china  celebrate achieve financial independence weektm this fall october    cellblockcom allows users to create collaborative cellphone photo albums and view the pictures as they arrive  celsion corporation successful in having american medical systems inc patent infringement suit dismissed in minnesota  central garden  pet announces marketing partnership with nascar legend richard petty  cereplast expands manufacturing facility to meet expected customer demand  changes in haldex group executive committee  chartone speeds medical record information access enhances security features with ewebrelease version   check point software to announce third quarter financial results on october   company overview  chevron unveils a promise to help in the fight against breast cancer  chinese stock markets in a delicate balance with thriving economy  chipless tags seem to be the most promising way to evolve to itemlevel rfid  chipx announces usbif compliance certification for usb  hs otg phy in structured asic  christopher  banks corporation expands board of directors  cimbix accepts us navy purchase order for military drinking water system in africa  circuit city signs deal with partsearch technologies  cirtran retains the rcg group  cisco tackles enterprise radio frequency challenges  citizen group to support  million in penalties against clean harbors plaquemine llc at october   court hearing  citrix gotowebinar helps mrinetwork to communicate more effectively with its  global franchises  city national bank names gregory t glover northside regional manager for core banking division  city of bellevue iowa selects trident optical access platform from wave optics for new municipal fttp network company overview  city university launches new mit program  claremont mckenna college to launch george r roberts faculty leadership initiative with  million gift  clarifi names founder gioel molinari president and ceo  clipblast to index video for websites unveils search box for site owners powering video search for site visitors  cmarket partners with meetup to help bring together fundraising organizers through local offline communities  cmgi to report fourth quarter and fiscal year  financial results  coastal financial corporation announces an increase in quarterly cash dividend  coffee sales driving the hot drinks market  cohu integrates agent video intelligences analytics software technology into its  series iview ii ip camera company overview  coldspark adds security software pioneer gregor freund to board of directors  colonial properties trust announces development of metropolitan midtown in charlotte north carolina  communicationelectronics command cecom awards ibaset m task order  companies finding it difficult to comply with everevolving securities transaction laws  compare your company against more than  manufacturing facilities across the us  compiere completes relocation to silicon valley  computerworld honors names network appliance ceo to chairmens committee  comtech telecommunications corp awarded  million of orders for satcom high power amplifiers  conagra foods names interim cfo search underway to fill position  concordia stena bulk in major deal with neste oil  connexion by boeing contract termination payments disclosure  conocophillips thirdquarter  interim update  consortium on reading excellence announces  literacy leadership summit  contivo selects liaison technologies as a preferred system integrator  cornet technology inc signs oem agreement with calient networks  corporate office properties trust announces third quarter  earnings conference call  correction fitch conference  webcast shareholder influences housing trends  the capital markets  covast network engines introduce the covast bb appliance for realtime networks  coverall cleaning concepts experts in cleaning healthcare facilities  crawfordsville indiana electric light  power selects wave optics trident optical access platform for muni fttp network  credit unions to learn proven commercial lending strategies during october   webcast  crocs inc enters into definitive agreement to acquire jibbitz llc  crosstex acquires natural gas treating business from cardinal gas solutions lp  cryptocard partners with valueadded reseller build bv to provide dutch businesses with truly userfriendly and costeffective twofactor authentication  csmg technologies announces live tissue connect subsidiary results at prestigious international eatsests surgical conference  csr joins wibree forum  ctr investments  consulting reaches managed it services agreement with thin line it services  cubist pharmaceuticals statement on the death of dr francis p tally  curis inc agrees to settlement with micromet ag  customer experience consultancy joins the allegiant group  cyberark announces partnership with courion to provide industrys first comprehensive identity and privileged user management solution  cypress announces date for annual analyst conference  cytrx scientific advisory board member dr craig c mello awarded nobel prize in medicine for rnai discovery  cytyc confirms dispatch of bidders statement and opening of its a cash per share unconditional offer for all of vision systems limited shares  da davidson  cos investment banking group serves as advisor on swiftview acquisition  daniel lalonde appointed president  ceo of louis vuitton na  datang mobile to distribute express logics threadxr rtos for gwireless phone handsets in china company overview  datapoint signs distributor agreement with jacada  david pollard and shane sullivan join wgnb wealth management a division of west georgia national bank  definition of ftth and broadband access terms released by the fiber to the home councils  degree controls announces data center energy seminar five ways to reduce data center energy costs  devon it to show new line of thin client terminals at citrix iforum  diagenic asa appoints erik christensen as managing director  digidata forms oem partnership with jmr  digimarc introduces smart card driver license  digimarc solutions discussed in interview with securitystockwatchcom  digital nirvana names john m stephens vice president of broadcast product development  digital river sponsors fifth international independent software developers forum  company overview  diomed holdings completes  million equity financing  direct pet health brings on licensed property and casualty insurance agent  disney offers adventures under the sea and gives the royal treatment with new handheld video games  distinguished alumni awards given by university of chicago business school  djo incorporated launches new headguard to reduce concussion risk in soccer  do you have the right mentors  docucorp announces enhancements to forms integrity manager solution  dont let the flu get you  select rite aid pharmacies to offer flu shots  donatwald named agency of record for waterfront media  donna n jennings appointed vice president of human resources at devry inc  doral financial corporation completes restructuring of mortgage loan transactions with rg premier bank  double fusion expands reach to sports gamers with online sports titles power football and manager zone  douglas lake minerals adds  gold prospecting licenses to its tanzanian portfolio  dr dorothy h bray to chair scientific advisory board at cytodyn  dr gary small named chief scientific advisor to dakim inc a provider of cognitive fitness solutions for the senior care industry  dresser masoneilan introduces new doubleacting digital positioner for use with all doubleacting actuators  dressing up your dog for halloween pet butler wants a photo for its howloween photo contest  drs technologies receives  million contract including options to provide decontamination systems for the us military company overview  dsm pharma michigan plant sale bucks pharmas continuing trend to shut em down an industrial info news alert  dts digital images selects xytech systems to manage post production workflow  dtshd master audio suite and dts surround audio suite launched  dutton associates announces investment opinion us energy rating raised to strong speculative buy by dutton associates  dws scudder expands defined contribution investment advisory solutions by adding managed accounts from morningstar associates through adp  dxp enterprises inc announces the opening of a new service center in cleburne texas  dynamotive receives australian license revenue  eva announces new service to track expenses for tax deductions  eaton vance credit opportunities fund report of earnings  eaton vance senior floatingrate trust report of earnings  echostar announces federal court blocks tivo injunction  econugenics inc reveals nihsponsored study results clinical report  ecora announces pci compliance webinar  ecora realizes over  new users in last  days  ecount and acb announce rewards and incentives partnership  edmundscom reports true cost of incentives consumers finding heavily discounted  models on many dealer lots  edwin j gillis elected to teradynes board  eegees restaurant chain acquired by ceo foods  eiqnetworks announces new security certification program company overview  elecom offers sandio tech advanced d laser mouse in japan  electric cloud introduces first end to end solution for software production management  elizabethtown gas to lower gas rate as winter approaches  elsevier mdl releases enhanced mdlr notebook   ema offers pcnalert service for efficient part change notification  emagin slated for two projects in latest dod appropriations bill  emaillabs launches new suite of ondemand consulting services  emerson leverages telecom expertise to enable fiber deployment company overview  emrise corporations subsidiary ro associates receives followon order for military power supplies  energy transfer partners lp announces agreement with centerpoint energy resources corp  enping city hosts more than  microphone makers and accounted for  percent of mainland chinas output in   enuclia semiconductor demonstrates pipeline video in yokohama japan  epicus communications appoints richard reiss senior consultant  equinix enhances its financial exchange platform with connectivity to chicago mercantile exchange  equity inns announces agreement with global hyatt  espns the contender season finale ranks as one of the highestrated eoe boxing telecasts in nine years  etrials worldwide announces share repurchase program  evans data corp enterprise survey indicates greater linux usage trends within large companies  examine the role of international arbitration in european commission competition law  experience wireless ps driving action in the palm of your hand with the fanatecr speedster controller  explore new business opportunities in the retailing industry in new zealand  express logics threadxr rtos now supported by lauterbachs trace debugger tools  express logics threadxr rtos powers arms new cortexr processor  exstreams dialogue software benefiting suntrust bank  extraordinary general meeting of aarhuskarlshamn ab november    facial care products leading the global skincare market industry overview  fact corporations flagship customer western bagel baking corporation expands distribution of alternative bageltm to walmart superstores  fasttrack to modernization for system iiseries applications  fat tuesday big payday in the big easy  federated completes sale of lord  taylor  first new york luxury fractional opens in the legendary st regis hotel  first research integrates industry leading financial metrics into industry profiles  firstever missouri seminar for municipalities interested in citywide wifi  firstclosetm announces the addition of inexpensive highly qualified and customized mortgage leads  fischer international eurekify team to define manage  automate rolebased identity management and compliance across all parts of the enterprise  fiserv de novo activity capitalizes on upturn in startup banks  fitch affirms  classes from  gsamp second lien transactions  places  on rating watch negative  fitch affirms banco rural sa outlook negative  fitch affirms lowes sr notes at a assigns a to b note issue  fitch affirms semgroups ratings assigns b to proposed sr unsecured notes  fitch conference  webcast shareholder influences housing trends and the capital markets  fitch places  classes of bear stearns bba on rating watch positive  fitch places  classes of bear stearns pbw on rwp  fitch rates amsis b assetbacked pt ctfs series arsi m  fitch rates cwabs mm mtge pt ctfs series   fitch rates cwalt mm mtge pt ctfs ser j  publications by namepublications by dateauthorsliterature ad eo pt uz before      a b c d e f g h i j k l m n o p q r s t u v w x y z a b c d e f g h i j k l m n o p q r s t u v w x y z terms of use  copyright   farlex inc  feedback  for webmasters   peter powchik ’ • about • purchase college skip to main content » top of page purchase college state university of new york purchase college icon search purchase college search main content about »  news about peter powchik ’ february   on the leadership team at regeneron pharmaceuticals and speed chess champion peter powchik ’ chemistry has had a successful career in clinical development at a wide range of leading pharmaceutical companies he is currently senior vice president for clinical development at regeneron pharmaceuticals in tarrytown ny a position he’s held since  he’s played a key role in successfully guiding important products for cancer eye disease and inflammatory conditions through clinical and regulatory processes and has had an impact on the development and commercialization of important new products that have changed the landscape for treatment of many diseases worldwide powchik went on to receive his md from new york university school of medicine aside from academics purchase had an impact his life in two more important ways first he met his wife of  years at campus center south he also honed speed chess skills that allowed him to earn pocket money playing chess on various street corners and parks in new york city—substantially reducing his need for student loans in medical school powchik received the purchase college president’s award for distinguished alumni at the commencement ceremony on friday may   peter powchik ’ save  share information for current students faculty and staff parents and families alumni local community need assistance contact us campus directory offices and services nys university police other resources email editor login your right to know privacy and accessibility employment visit campus give to purchase library share your story share an event take a class purchase college state university of new york  anderson hill road purchase ny    facebook twitter instagram youtube snapchat back to top of page » back to section navigation » site map » our team  regeneron leadership regeneron nasdaq regn is a leading science and technology company delivering lifetransforming medicines for serious diseases read on our robust research and development engine allows us to discover therapies that could have a profound impact on patient health read on our goal is to address serious medical conditions across multiple and diverse therapeutic areas our fdaapproved medicines are only the beginning of our longterm commitment to solve the human bodys most complex mysteries read on in addition to our work to invent new and needed medicines we are focused on improving our world and operating with the highest standards of integrity we are proud not only of what we do but how we do it read on our team our leadership team possesses rich and diverse industry knowledge a passion for science and a shared commitment to help transform lives made up of our founding scientists industry experts nobel laureates and members of the national academy of sciences we consistently push the boundaries of scientific excellence and discovery company leadership board of directors leonard s schleifer md phd george d yancopoulos md phd founder president and chief executive officer leonard s schleifer md phd founded the company in  while serving as an assistant professor of neurology at weill cornell medical college leveraging a lifelong passion for science and an entrepreneurial spirit he has served as a director and its president and chief executive officer since its inception and acted as chairman of the board from  through  dr schleifer received his md and phd in pharmacology from the university of virginia and he is a licensed physician certified in neurology by the american board of psychiatry and neurology len discusses his motivation for starting the company audio player not supported by browser if using safari quicktime is required president and chief scientific officer george d yancopoulos md phd is regeneron’s president and chief scientific officer in  he joined len schleifer md phd to launch regeneron george has been driven by science his entire life he began his education at the bronx high school of science received his md and phd from columbia university and went on to become the th most highly cited scientist in the world in the s in  he was elected to be a member of the national academy of sciences dr yancopoulos together with key members of his team is a principal inventor and developer of regenerons six fdaapproved drugs as well as its foundational technologies including the trap technology velocigene® and velocimmune® len and george reflect on their partnership audio player not supported by browser if using safari quicktime is required michael aberman md ned braunstein md thomas daly phd senior vice president strategy and investor relations michael aberman md joined regeneron in  and serves as senior vice president strategy and investor relations prior to joining regeneron dr aberman was a wall street research analyst covering the biotechnology industry in positions at credit suisse and morgan stanley before moving to wall street dr aberman was director of business development at antigenics inc an oncologyfocused biotechnology company dr aberman received his md from the university of toronto completed residency training in internal medicine at new yorkpresbyterian hospitalweill cornell medical center and received his mba from the wharton school of business senior vice president regulatory affairs  pharmacovigilance ned braunstein md joined regeneron in  and serves as senior vice president regulatory affairs prior to regeneron he worked at columbia university college of physicians and surgeons for  years as assistant and then associate professor of medicine and at merck  co inc for nine years in positions of increasing responsibility in clinical research regulatory affairs and global human health dr braunstein received his bs in medicine from northwestern university in evanston ill and his md from northwestern university in chicago senior vice president preclinical development  protein chemistry thomas daly phd joined regeneron in  he is senior vice president preclinical development  protein chemistry dr daly was previously vice president preclinical development  protein chemistry and before that held positions of increasing responsibility in protein sciences prior to regeneron dr daly served as a research scientist at repligen corporation dr daly received his phd in biochemistry from rice university and his bs in biochemistry from hofstra university james p fandl phd robert e landry joseph j larosa senior vice president protein expression sciences james p fandl phd joined regeneron in  as scientist in the protein expression group during his tenure at regeneron dr fandl has held numerous positions he was appointed vice president of protein expression sciences in  and senior vice president of protein expression sciences in  his research group developed the velocimab® suite of proprietary technologies including eesyr® fastr™ nice® and bst which enabled dr fandl to demonstrate his knack for acronyms he received his ab in biology from franklin  marshall college and his phd in microbiology from the university of california davis senior vice president finance and chief financial officer robert e landry joined the company in  as senior vice president finance and chief financial officer previously mr landry served as senior vice president and treasurer of pfizer inc prior to this position mr landry held a variety of us and international financial and general management positions at wyeth pharmaceuticals pfizer and pricewaterhousecoopers llp including at wyeths australian and new zealand affiliates he holds a bba in accounting from the university of notre dame senior vice president general counsel and secretary joseph j larosa has been senior vice president general counsel and secretary since september  previously mr larosa held a number of senior legal positions at scheringplough corporation where he was a corporate officer and served most recently as vice president legal affairs and as a member of the operations management team he also served as vice president global compliance and legal affairs at avon products inc most recently mr larosa was senior vice president general counsel and secretary at nycomed us inc mr larosa received his jd degree from new york university beth f levine jay s markowitz md andrew drew murphy phd senior vice president associate general counsel chief compliance officer beth levine joined regeneron in  and serves as senior vice president associate general counsel and chief compliance officer prior to joining regeneron beth spent  years at pfizer inc where she served in various positions in the legal division culminating in the role of general counsel  us pharmaceuticals followed by  months at keryx biopharmaceuticals inc as general counsel and chief compliance officer in the early days of her legal career beth was a litigation associate at the law firm of paul weiss rifkind wharton  garrison following a judicial clerkship with us district judge gerard l goettel of the southern district of new york beth received a bs from cornell university and a jd from fordham law school senior vice president portfolio management jay s markowitz md joined regeneron in  as senior vice president portfolio management dr markowitz was previously at capital world investors where he was a us pharmaceutical and biotechnology analyst and portfolio manager prior to capital world investors dr markowitz was a biotechnology analyst and portfolio manager at t rowe price before transitioning to an investment career he was an assistant professor and transplant surgeon at the johns hopkins university school of medicine dr markowitz received his md from duke university and his ba from columbia university senior vice president research regeneron laboratories drew murphy phd joined regeneron in  as director of genomics and bioinformatics he has led the gene discovery and bioinformatics group and the target discovery group and is now the senior vice president of regeneron laboratories dr murphy is a coinventor of several of regenerons key technologies — velocigene® and velocimmune® — and continues to lead several technology centers and therapeutic focus areas prior to joining regeneron dr murphy worked for seven years at cadus pharmaceuticals he received his bs in molecular biology at the university of wisconsin and his phd in human genetics from columbia university college of physicians and surgeons sally a paull peter powchik md nicholas papadopoulos phd senior vice president human resources sally a paull joined regeneron as senior vice president human resources in  ms paull was previously executive vice president chief human resources officer at inova health system prior to inova she was senior vice president chief human resources officer at forest laboratories earlier in her career ms paull served in progressively senior human resources roles at dentsply international she received her ba from the united states air force academy and an mair from the university of delaware senior vice president clinical development peter powchik md has been senior vice president clinical development since october  prior to joining the company dr powchik served as senior vice president and chief medical officer at chugai pharma usa a position he held from may  until october  from april  until may  he held various senior clinical development positions at novartis pharmaceuticals corporation most recently as vice president us clinical development and medical affairs dr powchik held various clinical development positions with sepracor inc and pfizer inc from october  to april  dr powchik received his md from new york university school of medicine senior vice president research  development operations nicholas papadopoulos phd joined regeneron in  as a scientist in the protein sciences department in  dr papadopoulos was named senior director of therapeutic proteins with responsibilities dedicated to overseeing the generation of fully human velocimmune® antibodies he was named vice president in  and senior vice president in january  he received his bs in chemistry from the state university of new york and his phd in chemistry from the pennsylvania state university dr papadopoulos completed his postdoctoral training in the department of microbiology and immunology at the albert einstein college of medicine neil stahl phd robert j terifay daniel van plew executive vice president research and development neil stahl phd is executive vice president research and development dr stahl started his career at regeneron as a staff scientist in discovery research in  working on cytokine receptor signaling he spearheaded the invention and development of regenerons trap technology which provided the basis of regenerons first three approved drugs he also built the preclinical development team for the company and has overseen indenabling activities of over  therapeutic candidates dr stahl received his phd in biochemistry from brandeis university and then conducted postdoctoral research at the university of california san francisco before joining the company neil explains why he joined the regeneron team audio player not supported by browser if using safari quicktime is required executive vice president commercial robert j terifay is executive vice president commercial prior to joining regeneron mr terifay served as president and chief operating officer of arginox pharmaceuticals inc senior vice president business operations at synta pharmaceuticals corp senior vice president oncology commercial at millennium pharmaceuticals inc vice president marketing at cor therapeutics inc executive vice president of strategic services at saatchi  saatchi and held various commercial and marketing positions at gd searle  company mr terifay received a master of management degree in marketing and health service management from the jl kellogg graduate school of management northwestern university executive vice president and general manager industrial operations and product supply daniel van plew has been executive vice president and general manager industrial operations and product supply since january  he joined the company in july  previously serving as senior vice president vice president and general manager industrial operations and product supply prior to his tenure at regeneron mr van plew served as executive vice president rd and technical operations of crucell holland bv senior director vacaville operations at chiron biopharmaceuticals part of chiron corporation and various managerial positions in the health and life sciences practice of accenture ltd mr van plew received an msc in chemistry from the pennsylvania state university and an mba from michigan state university daniels perspective on why regeneron is unique audio player not supported by browser if using safari quicktime is required david weinreich md mba senior vice president global clinical development david weinreich md joined regeneron as senior vice president late stage clinical development and medical affairs in  dr weinreich was previously the senior vice president and head of global development for specialty medicine at bayer pharmaceuticals prior to bayer dr weinreich held positions of increasing responsibility focused on the development of oncology molecules at amgen dr weinreich also previously served as vice president of clinical affairs at gene logic and as an independent consultant helping small to midstage biotechnology companies with drug commercialization dr weinreich received his md from boston university school of medicine his mba from the mcdonough school of business at georgetown university and his bs in computer engineering from columbia university leonard s schleifer md phd founder president and chief executive officer leonard s schleifer md phd founded the company in  while serving as an assistant professor of neurology at weill cornell medical college leveraging a lifelong passion for science and an entrepreneurial spirit he has served as a director and its president and chief executive officer since its inception and acted as chairman of the board from  through  dr schleifer received his md and phd in pharmacology from the university of virginia and he is a licensed physician certified in neurology by the american board of psychiatry and neurology len discusses his motivation for starting the company audio player not supported by browser if using safari quicktime is required george d yancopoulos md phd president and chief scientific officer george d yancopoulos md phd is regeneron’s president and chief scientific officer in  he joined len schleifer md phd to launch regeneron george has been driven by science his entire life he began his education at the bronx high school of science received his md and phd from columbia university and went on to become the th most highly cited scientist in the world in the s in  he was elected to be a member of the national academy of sciences dr yancopoulos together with key members of his team is a principal inventor and developer of regenerons six fdaapproved drugs as well as its foundational technologies including the trap technology velocigene® and velocimmune® len and george reflect on their partnership audio player not supported by browser if using safari quicktime is required michael aberman md senior vice president strategy and investor relations michael aberman md joined regeneron in  and serves as senior vice president strategy and investor relations prior to joining regeneron dr aberman was a wall street research analyst covering the biotechnology industry in positions at credit suisse and morgan stanley before moving to wall street dr aberman was director of business development at antigenics inc an oncologyfocused biotechnology company dr aberman received his md from the university of toronto completed residency training in internal medicine at new yorkpresbyterian hospitalweill cornell medical center and received his mba from the wharton school of business ned braunstein md senior vice president regulatory affairs  pharmacovigilance ned braunstein md joined regeneron in  and serves as senior vice president regulatory affairs prior to regeneron he worked at columbia university college of physicians and surgeons for  years as assistant and then associate professor of medicine and at merck  co inc for nine years in positions of increasing responsibility in clinical research regulatory affairs and global human health dr braunstein received his bs in medicine from northwestern university in evanston ill and his md from northwestern university in chicago thomas daly phd senior vice president preclinical development  protein chemistry thomas daly phd joined regeneron in  he is senior vice president preclinical development  protein chemistry dr daly was previously vice president preclinical development  protein chemistry and before that held positions of increasing responsibility in protein sciences prior to regeneron dr daly served as a research scientist at repligen corporation dr daly received his phd in biochemistry from rice university and his bs in biochemistry from hofstra university james p fandl phd senior vice president protein expression sciences james p fandl phd joined regeneron in  as scientist in the protein expression group during his tenure at regeneron dr fandl has held numerous positions he was appointed vice president of protein expression sciences in  and senior vice president of protein expression sciences in  his research group developed the velocimab® suite of proprietary technologies including eesyr® fastr™ nice® and bst which enabled dr fandl to demonstrate his knack for acronyms he received his ab in biology from franklin  marshall college and his phd in microbiology from the university of california davis robert e landry senior vice president finance and chief financial officer robert e landry joined the company in  as senior vice president finance and chief financial officer previously mr landry served as senior vice president and treasurer of pfizer inc prior to this position mr landry held a variety of us and international financial and general management positions at wyeth pharmaceuticals pfizer and pricewaterhousecoopers llp including at wyeths australian and new zealand affiliates he holds a bba in accounting from the university of notre dame joseph j larosa senior vice president general counsel and secretary joseph j larosa has been senior vice president general counsel and secretary since september  previously mr larosa held a number of senior legal positions at scheringplough corporation where he was a corporate officer and served most recently as vice president legal affairs and as a member of the operations management team he also served as vice president global compliance and legal affairs at avon products inc most recently mr larosa was senior vice president general counsel and secretary at nycomed us inc mr larosa received his jd degree from new york university beth f levine senior vice president associate general counsel chief compliance officer beth levine joined regeneron in  and serves as senior vice president associate general counsel and chief compliance officer prior to joining regeneron beth spent  years at pfizer inc where she served in various positions in the legal division culminating in the role of general counsel  us pharmaceuticals followed by  months at keryx biopharmaceuticals inc as general counsel and chief compliance officer in the early days of her legal career beth was a litigation associate at the law firm of paul weiss rifkind wharton  garrison following a judicial clerkship with us district judge gerard l goettel of the southern district of new york beth received a bs from cornell university and a jd from fordham law school jay s markowitz md senior vice president portfolio management jay s markowitz md joined regeneron in  as senior vice president portfolio management dr markowitz was previously at capital world investors where he was a us pharmaceutical and biotechnology analyst and portfolio manager prior to capital world investors dr markowitz was a biotechnology analyst and portfolio manager at t rowe price before transitioning to an investment career he was an assistant professor and transplant surgeon at the johns hopkins university school of medicine dr markowitz received his md from duke university and his ba from columbia university andrew drew murphy phd senior vice president research regeneron laboratories drew murphy phd joined regeneron in  as director of genomics and bioinformatics he has led the gene discovery and bioinformatics group and the target discovery group and is now the senior vice president of regeneron laboratories dr murphy is a coinventor of several of regenerons key technologies – velocigene® and velocimmune® – and continues to lead several technology centers and therapeutic focus areas prior to joining regeneron dr murphy worked for seven years at cadus pharmaceuticals he received his bs in molecular biology at the university of wisconsin and his phd in human genetics from columbia university college of physicians and surgeons nicholas papadopoulos phd senior vice president research  development operations nicholas papadopoulos phd joined regeneron in  as a scientist in the protein sciences department in  dr papadopoulos was named senior director of therapeutic proteins with responsibilities dedicated to overseeing the generation of fully human velocimmune® antibodies he was named vice president in  and senior vice president in january  he received his bs in chemistry from the state university of new york and his phd in chemistry from the pennsylvania state university dr papadopoulos completed his postdoctoral training in the department of microbiology and immunology at the albert einstein college of medicine sally a paull senior vice president human resources sally a paull joined regeneron as senior vice president human resources in  ms paull was previously executive vice president chief human resources officer at inova health system prior to inova she was senior vice president chief human resources officer at forest laboratories earlier in her career ms paull served in progressively senior human resources roles at dentsply international she received her ba from the united states air force academy and an mair from the university of delaware peter powchik md senior vice president clinical development peter powchik md has been senior vice president clinical development since october  prior to joining the company dr powchik served as senior vice president and chief medical officer at chugai pharma usa a position he held from may  until october  from april  until may  he held various senior clinical development positions at novartis pharmaceuticals corporation most recently as vice president us clinical development and medical affairs dr powchik held various clinical development positions with sepracor inc and pfizer inc from october  to april  dr powchik received his md from new york university school of medicine neil stahl phd executive vice president research and development neil stahl phd is executive vice president research and development dr stahl started his career at regeneron as a staff scientist in discovery research in  working on cytokine receptor signaling he spearheaded the invention and development of regenerons trap technology which provided the basis of regenerons first three approved drugs he also built the preclinical development team for the company and has overseen indenabling activities of over  therapeutic candidates dr stahl received his phd in biochemistry from brandeis university and then conducted postdoctoral research at the university of california san francisco before joining the company neil explains why he joined the regeneron team audio player not supported by browser if using safari quicktime is required robert j terifay executive vice president commercial robert j terifay is executive vice president commercial prior to joining regeneron mr terifay served as president and chief operating officer of arginox pharmaceuticals inc senior vice president business operations at synta pharmaceuticals corp senior vice president oncology commercial at millennium pharmaceuticals inc vice president marketing at cor therapeutics inc executive vice president of strategic services at saatchi  saatchi and held various commercial and marketing positions at gd searle  company mr terifay received a master of management degree in marketing and health service management from the jl kellogg graduate school of management northwestern university daniel van plew executive vice president and general manager industrial operations and product supply daniel van plew has been executive vice president and general manager industrial operations and product supply since january  he joined the company in july  previously serving as senior vice president vice president and general manager industrial operations and product supply prior to his tenure at regeneron mr van plew served as executive vice president rd and technical operations of crucell holland bv senior director vacaville operations at chiron biopharmaceuticals part of chiron corporation and various managerial positions in the health and life sciences practice of accenture ltd mr van plew received an msc in chemistry from the pennsylvania state university and an mba from michigan state university daniels perspective on why regeneron is unique audio player not supported by browser if using safari quicktime is required david weinreich md mba senior vice president global clinical development david weinreich md joined regeneron as senior vice president late stage clinical development and medical affairs in  dr weinreich was previously the senior vice president and head of global development for specialty medicine at bayer pharmaceuticals prior to bayer dr weinreich held positions of increasing responsibility focused on the development of oncology molecules at amgen dr weinreich also previously served as vice president of clinical affairs at gene logic and as an independent consultant helping small to midstage biotechnology companies with drug commercialization dr weinreich received his md from boston university school of medicine his mba from the mcdonough school of business at georgetown university and his bs in computer engineering from columbia university p roy vagelos md charles a baker bonnie l bassler phd chairman of the board retired chairman of the board and chief executive officer merck  co inc p roy vagelos md has been chairman of the board of the company since january  prior to joining regeneron dr vagelos was chairman of the board and chief executive officer of merck  co inc he joined merck in  became a director in  president and chief executive officer in  and chairman in  dr vagelos retired from all positions with merck in  dr vagelos was on the board of directors of theravance inc through april  len george and roy discuss how len recruited roy audio player not supported by browser if using safari quicktime is required retired chairman of the board president and chief executive officer of the liposome company inc charles a baker has been a director of the company since february  in september  mr baker retired as chairman president and chief executive officer of the liposome company inc a position he had held since december  during his career mr baker served in a senior management capacity in various pharmaceutical companies including tenures as group vice president squibb corporation now bristolmyers squibb president squibb international and various senior executive positions at abbott laboratories and pfizer inc mr baker is currently a member of the board of directors of progenics pharmaceuticals inc chair department of molecular biology and squibb professor in molecular biology princeton university bonnie l bassler phd joined the board in  she is currently the chair of the department of molecular biology and the squibb professor in molecular biology at princeton university and a howard hughes medical institute investigator dr bassler has previously served as the president of the american society for microbiology as well as on the boards for the american association for the advancement of science the national science foundation and the american academy of microbiology she has been elected to the national academy of sciences the american academy of arts and sciences the royal society and the american philosophical society and has received many scientific honors including a macarthur foundation fellowship the lounsbery award and the shaw prize for life science and medicine dr bassler received her bsc from the university of california davis and her phd in biochemistry from johns hopkins university she served as a postdoctoral fellow and research scientist at the agouron institute in la jolla ca before becoming a faculty member at princeton university michael s brown md tony coles md joseph l goldstein md regental professor of molecular genetics and internal medicine director erik jonsson center for molecular genetics the university of texas southwestern medical center at dallas michael s brown md has been a director of the company since june  dr brown holds the distinguished chair in biomedical sciences a position he has held since  is a regental professor of molecular genetics and internal medicine and the director of the erik jonsson center for molecular genetics and human disease at the university of texas southwestern medical center at dallas positions he has held since  dr brown and dr joseph goldstein jointly received the nobel prize for physiology or medicine in  dr brown is a member of the national academy of sciences the institute of medicine and foreign member of the royal society london dr brown served as a member of the board of directors of pfizer inc until april  chairman and chief executive officer yumanity therapeutics llc dr coles age  has served as chairman and chief executive officer of yumanity therapeutics llc a company focused on transforming drug discovery for neurodegenerative diseases since october  prior to this from october  dr coles served as chairman and ceo of trate enterprises llc a privately held company dr coles served as president chief executive officer and chairman of the board of onyx pharmaceuticals inc a biopharmaceutical company from  until  having served as its president chief executive officer and a member of its board of directors from  until  prior to joining onyx in  he was president chief executive officer and a member of the board of directors of nps pharmaceuticals inc a biopharmaceutical company before joining nps in  he served in various leadership positions in the biopharmaceutical and pharmaceutical industries including at merck  co inc bristolmyers squibb company and vertex pharmaceuticals incorporated in addition to having previously served as a director of onyx and nps he was formerly a director of laboratory corporation of america holdings and campus crest communities inc dr coles has been a director of mckesson corporation since april  and serves on the compensation committee and the finance committee of its board of directors he has also served as chairman of the board of directors of crispr therapeutics ag since october  and serves on its compensation committee and nominating and corporate governance committee regental professor and chairman department of molecular genetics the university of texas southwestern center at dallas joseph l goldstein md has been a director of the company since june  dr goldstein has been professor of medicine and genetics and chairman of the department of molecular genetics at the university of texas southwestern medical center at dallas since  dr goldstein is a member of the national academy of sciences drs goldstein and brown jointly received the nobel prize for physiology or medicine in  christine a poon arthur f ryan leonard s schleifer md phd professor in the department of management and human resources at the max m fisher college of business the ohio state university christine a poon has been a director of the company since  ms poon is a professor in the department of management and human resources at the max m fisher college of business at the ohio state university where she served as dean and the john w berry sr chair in business from  to  prior to joining fisher ms poon spent  years in the healthcare industry most recently as vice chairman and worldwide chairman of pharmaceuticals at johnson  johnson where she served on the companys board of directors and executive committee and was responsible for managing the pharmaceutical businesses of the company her areas of expertise include domestic and international business operations and sales and marketing prior to joining johnson  johnson she spent  years at bristolmyers squibb ms poon is on the board of directors of prudential financial inc and the supervisory board of royal philips electronics she was named woman of the year by the healthcare businesswomens association in  and named business leader of the future by cnbcwall street journal in  retired chairman of the board and chief executive officer prudential financial inc arthur f ryan has been a director of the company since january  in  mr ryan retired as the chairman and chief executive officer of prudential financial inc one of the largest diversified financial institutions in the world prior to joining prudential mr ryan served as president and chief operating officer of chase manhattan bank where he also ran chases worldwide retail bank from  to  mr ryan served as a nonexecutive director of the royal bank of scotland group plc president and chief executive officer leonard s schleifer md phd founded the company in  while serving as an assistant professor of neurology at weill cornell medical college leveraging a lifelong passion for science and an entrepreneurial spirit he has served as a director and its president and chief executive officer since its inception and acted as chairman of the board from  through  dr schleifer received his md and phd in pharmacology from the university of virginia he is a licensed physician certified in neurology by the american board of psychiatry and neurology george l sing marc tessierlavigne phd george d yancopoulos md phd managing director lancet capital george l sing has been a director of the company since january  during which time he also held the position of managing director of lancet capital a venture capital investment firm in the healthcare field mr sing has also served as chief executive officer of stemnion inc a biomedical company in the regenerative medicine field president the rockefeller university marc tessierlavigne phd has been a director of the company since november  dr tessierlavigne was appointed as the president of stanford university in september  from march  to august  he served as the president of the rockefeller university previously he served as executive vice president and chief scientific officer at genentech inc which he joined in  he was a professor at stanford and at the university of california san francisco dr tessierlavigne a leader in the field of brain development is a member of the national academy of sciences and its institute of medicine and a fellow of the royal societies of the united kingdom and canada president and chief scientific officer george d yancopoulos md phd joined the company in  and is president and chief scientific officer dr yancopoulos has been driven by science his entire life he began his education at the bronx high school of science received his md and phd from columbia university and went on to become the th most highly cited scientist in the world in the s in  he was elected to be a member of the national academy of sciences dr yancopoulos together with key members of his team is a principal inventor and developer of regenerons six fdaapproved drugs as well as its foundational technologies including the trap technology velocigene® and velocimmune® huda y zoghbi md professor departments of pediatrics molecular and human genetics and neurology and neuroscience baylor college director jan and dan duncan neurological research institute at texas childrens hospital huda y zoghbi md joined the board in  dr zoghbi is currently a professor in the departments of pediatrics molecular and human genetics and neurology and neuroscience at baylor college of medicine the director of the jan and dan duncan neurological research institute at texas childrens hospital and an investigator of the howard hughes medical institute she has been elected to the national academy of sciences the institute of medicine and the american association for the advancement of science and has been awarded numerous recognitions for her work including the pearl meister greengard prize the march of dimes prize in developmental biology and the vanderbilt prize in biomedical science dr zoghbi earned her bsc from the american university of beirut received her md from meharry medical college in nashville tn and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at baylor college of medicine where she then pursued postdoctoral research training in molecular genetics p roy vagelos md chairman of the board retired chairman of the board and chief executive officer merck  co inc p roy vagelos md has been chairman of the board of the company since january  prior to joining regeneron dr vagelos was chairman of the board and chief executive officer of merck  co inc he joined merck in  became a director in  president and chief executive officer in  and chairman in  dr vagelos retired from all positions with merck in  dr vagelos was on the board of directors of theravance inc through april  len george and roy discuss how len recruited roy audio player not supported by browser if using safari quicktime is required charles a baker retired chairman of the board president and chief executive officer of the liposome company inc charles a baker has been a director of the company since february  in september  mr baker retired as chairman president and chief executive officer of the liposome company inc a position he had held since december  during his career mr baker served in a senior management capacity in various pharmaceutical companies including tenures as group vice president squibb corporation now bristolmyers squibb president squibb international and various senior executive positions at abbott laboratories and pfizer inc mr baker is currently a member of the board of directors of progenics pharmaceuticals inc bonnie l bassler phd chair department of molecular biology and squibb professor in molecular biology princeton university bonnie l bassler phd joined the board in  she is currently the chair of the department of molecular biology and the squibb professor in molecular biology at princeton university and a howard hughes medical institute investigator dr bassler has previously served as the president of the american society for microbiology as well as on the boards for the american association for the advancement of science the national science foundation and the american academy of microbiology she has been elected to the national academy of sciences the american academy of arts and sciences the royal society and the american philosophical society and has received many scientific honors including a macarthur foundation fellowship the lounsbery award and the shaw prize for life science and medicine dr bassler received her bsc from the university of california davis and her phd in biochemistry from johns hopkins university she served as a postdoctoral fellow and research scientist at the agouron institute in la jolla ca before becoming a faculty member at princeton university michael s brown md regental professor of molecular genetics and internal medicine director erik jonsson center for molecular genetics the university of texas southwestern medical center at dallas michael s brown md has been a director of the company since june  dr brown holds the distinguished chair in biomedical sciences a position he has held since  is a regental professor of molecular genetics and internal medicine and the director of the erik jonsson center for molecular genetics and human disease at the university of texas southwestern medical center at dallas positions he has held since  dr brown and dr joseph goldstein jointly received the nobel prize for physiology or medicine in  dr brown is a member of the national academy of sciences the institute of medicine and foreign member of the royal society london dr brown served as a member of the board of directors of pfizer inc until april  tony coles md chairman and chief executive officer yumanity therapeutics llc dr coles age  has served as chairman and chief executive officer of yumanity therapeutics llc a company focused on transforming drug discovery for neurodegenerative diseases since october  prior to this from october  dr coles served as chairman and ceo of trate enterprises llc a privately held company dr coles served as president chief executive officer and chairman of the board of onyx pharmaceuticals inc a biopharmaceutical company from  until  having served as its president chief executive officer and a member of its board of directors from  until  prior to joining onyx in  he was president chief executive officer and a member of the board of directors of nps pharmaceuticals inc a biopharmaceutical company before joining nps in  he served in various leadership positions in the biopharmaceutical and pharmaceutical industries including at merck  co inc bristolmyers squibb company and vertex pharmaceuticals incorporated in addition to having previously served as a director of onyx and nps he was formerly a director of laboratory corporation of america holdings and campus crest communities inc dr coles has been a director of mckesson corporation since april  and serves on the compensation committee and the finance committee of its board of directors he has also served as chairman of the board of directors of crispr therapeutics ag since october  and serves on its compensation committee and nominating and corporate governance committee joseph l goldstein md regental professor and chairman department of molecular genetics the university of texas southwestern center at dallas joseph l goldstein md has been a director of the company since june  dr goldstein has been professor of medicine and genetics and chairman of the department of molecular genetics at the university of texas southwestern medical center at dallas since  dr goldstein is a member of the national academy of sciences drs goldstein and brown jointly received the nobel prize for physiology or medicine in  christine a poon professor in the department of management and human resources at the max m fisher college of business the ohio state university christine a poon has been a director of the company since  ms poon is a professor in the department of management and human resources at the max m fisher college of business at the ohio state university where she served as dean and the john w berry sr chair in business from  to  prior to joining fisher ms poon spent  years in the healthcare industry most recently as vice chairman and worldwide chairman of pharmaceuticals at johnson  johnson where she served on the companys board of directors and executive committee and was responsible for managing the pharmaceutical businesses of the company her areas of expertise include domestic and international business operations and sales and marketing prior to joining johnson  johnson she spent  years at bristolmyers squibb ms poon is on the board of directors of prudential financial inc and the supervisory board of royal philips electronics she was named woman of the year by the healthcare businesswomens association in  and named business leader of the future by cnbcwall street journal in  arthur f ryan retired chairman of the board and chief executive officer prudential financial inc arthur f ryan has been a director of the company since january  in  mr ryan retired as the chairman and chief executive officer of prudential financial inc one of the largest diversified financial institutions in the world prior to joining prudential mr ryan served as president and chief operating officer of chase manhattan bank where he also ran chases worldwide retail bank from  to  mr ryan served as a nonexecutive director of the royal bank of scotland group plc leonard s schleifer md phd president and chief executive officer leonard s schleifer md phd founded the company in  while serving as an assistant professor of neurology at weill cornell medical college leveraging a lifelong passion for science and an entrepreneurial spirit he has served as a director and its president and chief executive officer since its inception and acted as chairman of the board from  through  dr schleifer received his md and phd in pharmacology from the university of virginia he is a licensed physician certified in neurology by the american board of psychiatry and neurology george l sing managing director lancet capital george l sing has been a director of the company since january  during which time he also held the position of managing director of lancet capital a venture capital investment firm in the healthcare field mr sing has also served as chief executive officer of stemnion inc a biomedical company in the regenerative medicine field marc tessierlavigne phd president the rockefeller university marc tessierlavigne phd has been a director of the company since november  dr tessierlavigne was appointed as the president of stanford university in september  from march  to august  he served as the president of the rockefeller university previously he served as executive vice president and chief scientific officer at genentech inc which he joined in  he was a professor at stanford and at the university of california san francisco dr tessierlavigne a leader in the field of brain development is a member of the national academy of sciences and its institute of medicine and a fellow of the royal societies of the united kingdom and canada george d yancopoulos md phd president and chief scientific officer george d yancopoulos md phd joined the company in  and is president and chief scientific officer dr yancopoulos has been driven by science his entire life he began his education at the bronx high school of science received his md and phd from columbia university and went on to become the th most highly cited scientist in the world in the s in  he was elected to be a member of the national academy of sciences dr yancopoulos together with key members of his team is a principal inventor and developer of regenerons six fdaapproved drugs as well as its foundational technologies including the trap technology velocigene® and velocimmune® huda y zoghbi md professor departments of pediatrics molecular and human genetics and neurology and neuroscience baylor college director jan and dan duncan neurological research institute at texas childrens hospital huda y zoghbi md joined the board in  dr zoghbi is currently a professor in the departments of pediatrics molecular and human genetics and neurology and neuroscience at baylor college of medicine the director of the jan and dan duncan neurological research institute at texas childrens hospital and an investigator of the howard hughes medical institute she has been elected to the national academy of sciences the institute of medicine and the american association for the advancement of science and has been awarded numerous recognitions for her work including the pearl meister greengard prize the march of dimes prize in developmental biology and the vanderbilt prize in biomedical science dr zoghbi earned her bsc from the american university of beirut received her md from meharry medical college in nashville tn and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at baylor college of medicine where she then pursued postdoctoral research training in molecular genetics you are now leaving regeneroncom the site you are about to visit is maintained by a third party who is solely responsible for its content we encourage you to read the privacy policy of every website you visit cancel continue you are now leaving regeneroncom to visit another regeneron pharmaceuticals website cancel continue confirmed thank you for reaching out to us well be in touch soon